Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23145891 | 0.81 | NPSR1 (0.83) | NPSR1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL20447427 | 0.79 | NPSR1 (0.59) | NPSR1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL27246623 | 0.77 | NPSR1 (0.57) | NPSR1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL788049 | 0.77 | CA1 (0.37) | NPSR1CA1CA2CA9CA12 | |
| SCHEMBL21798343 | 0.76 | NPSR1 (0.55) | NPSR1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL21798350 | 0.74 | NPSR1 (0.53) | NPSR1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL21798311 | 0.74 | NPSR1 (0.53) | NPSR1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL4892039 | 0.71 | NPSR1 (0.67) | NPSR1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL7971343 | 0.70 | CA1 (0.30) | CA1CA2CA9CA5A | |
| SCHEMBL21797972 | 0.70 | NPSR1 (0.53) | NPSR1CYP3A4CYP2C9PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688741-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | Meta-Immune, Inc. (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-12459932-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4514790-A1 | COMPOUNDS FOR INHIBITING KIF18A | Volastra Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119451951-A | Compounds for inhibition of KIF18A | 沃拉斯查疗法公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024249867-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | AM SCIENCES (KR) | 2024-12-05 | — | — | WO | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2023212240-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212240-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-8129367-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129367-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129367-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| CN-101918406-A | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2010-12-15 | — | — | CN | disclosed |
| EP-2209784-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009067481-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067481-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090130057-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-21 | — | — | US | disclosed |
| US-20090130057-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-21 | — | — | US | disclosed |
| US-20090130057-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | NPSR1 4661/4885CYP3A4 4874/4885CYP2C9 4878/4885 |
| US-12459932-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | NPSR1 4374/4885CYP3A4 4022/4885CYP2C9 3846/4885 |
| US-20090130057-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | NPSR1 2998/4885CYP3A4 214/4885CYP2C9 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.